Skip to main content

Advertisement

SpringerLink
Log in

Resectability of rectal cancer after neoadjuvant treatment – current status

  • ICS congress 2015
  • Published:
European Surgery Aims and scope Submit manuscript

Abstract

Background

The purpose of the study was to compare our experience to recent trends of multimodal treatment of patients with locally advanced rectal cancer.

Patients and methods

209 patients with histologically proven adenocarcinoma of the rectum were treated for 3 years by a multimodal approach in a single center. Patients were evaluated for clinical and pathologic response. The type of surgical procedure and the number of retrieved lymph nodes and postoperative complications were recorded.

Results

Neoadjuvant Chemoradiotherapy (CRT) had a downstaging effect in more than half of our patients (50.61 %), and about one quarter of them achieved a complete pathologic response (22.22 %).

Conclusions

Preoperative CRT produced an encouraging down-staging effect with acceptable toxicity and perioperative complications.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ferenschild FT, Dawson I, de Graaf EJ, de Wilt JH, Tetteroo GW. Preoperative radiotherapy has no value for patients with T2–3, N0 adenocarcinomas of the rectum. Dig Surg. 2009;26(4):291–296. doi:10.1159/000227771..

    Article  PubMed  Google Scholar 

  2. Rödel C, Trojan J, Bechstein WO, Woeste G. Neoadjuvant short- or long-term radio(chemo)therapy for rectal cancer: how and who should be treated? Dig Dis. 2012;30(2):102–108. doi:10.1159/000342038.

    Article  PubMed  Google Scholar 

  3. Van Gijn, et al. Dutch Colorectal Cancer Group. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol. 2011;12:575–582.

    Article  PubMed  Google Scholar 

  4. Valentini V. Tumor regression grading in rectal cancer: is it time to move forward? J Clin Oncol. 2014;32(15):1534–1536.

    Article  PubMed  Google Scholar 

  5. Kulu Y, Ulrich A, Buchler MW. Resectable rectal cancer: Which patient does not need preoperative radiotherapy? Dig Dis. 2012;30(2):118–125.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgical Oncology, Saint Elisabeth Cancer Institute and Faculty of Medicine, Comenius University Bratislava, Heydukova 10, 81250, Bratislava, Slovak republic

    M. Sabol MD PhD, R. Donát, P. Chvalný, J. Palaj, D. Dyttert, P. Mračna & Š. Durdík

Authors
  1. M. Sabol MD PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. Donát
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P. Chvalný
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. Palaj
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D. Dyttert
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. P. Mračna
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Š. Durdík
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Sabol MD PhD.

Ethics declarations

Conflict of interest

M. Sabol, R. Donát, P. Chvalný, J. Palaj, D. Dyttert, P. Mračna and Š. Durdík state that there are no conflicts of interest.

Ethical standards

All the patients included in study gave written consent prior to both radiotherapy and surgical procedure.

Additional information

The supplement is dedicated to Jubilee World congress of International College of Surgeons 2015.

The publishing was sponsored by the Ministry of Health of the Czech Republic.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sabol, M., Donát, R., Chvalný, P. et al. Resectability of rectal cancer after neoadjuvant treatment – current status. Eur Surg 48 (Suppl 2), 163–165 (2016). https://doi.org/10.1007/s10353-016-0404-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10353-016-0404-6

Keywords

Search

Navigation